Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older
• People whose overall health and ability to carry out daily activities meets a certain minimum level (measured on a standard scale used by doctors, called ECOG Performance Status of 3 or below)
• People who have been diagnosed through a tissue biopsy with either primary CNS lymphoma (lymphoma that started in the brain or spinal cord) or a type of aggressive lymphoma called diffuse large B-cell lymphoma (DLBCL) that has spread to the brain or spinal cord, AND who either: have had the disease come back or stop responding to at least one previous treatment, OR have been assessed by their treating doctor as not suitable for a standard chemotherapy treatment called high-dose methotrexate (for example, due to kidney problems, liver disease, or heart failure)
• People whose tumours are suitable for a focused radiation treatment called stereotactic radiosurgery (SRS) — meaning each tumour is smaller than 6 cm and there are fewer than 10 tumours in total
• People who have measurable disease visible on brain scans or detectable in the fluid around the brain and spinal cord
• People whose blood counts, liver function, and kidney function meet minimum levels set by the trial (a trial doctor will assess this through blood tests)
• People who are not able to become pregnant, or people who are able to become pregnant but have a negative pregnancy test and agree to use highly effective contraception for a specified period after the last dose of study treatments; male participants with female partners who could become pregnant must also agree to use highly effective contraception for a set period after their last dose
• People who are able to give written consent to participate, or who have a legally authorised representative who can do so on their behalf if they are unable to

Who may not be able to join:

• People currently receiving other cancer treatments (other than corticosteroids/steroids)
• People who have had bleeding in the brain or a significant stroke within the past 6 months
• People who have previously had radiation treatment to the brain or spinal cord
• People with serious medical conditions that a doctor determines would make the risks of the trial too high — including a heart attack in the past 6 months, unstable chest pain, uncontrolled diabetes, serious active infections, severely weakened immune system, or significant heart failure
• People with known bleeding disorders (such as von Willebrand's disease or haemophilia) or who are actively bleeding
• People with a known HIV infection
• People who have previously had a donor (allogeneic) stem cell transplant — note that a transplant using the person's own cells (autologous) does not exclude participation
• People who have previously received the study drug loncastuximab tesirine
• People who have received chemotherapy, targeted cancer medicines, or other CNS lymphoma treatments too recently before the start of the trial (specific timeframes apply depending on the type of treatment — confirm with trial site)
• People who have not yet recovered sufficiently from side effects of previous cancer treatments (with some exceptions — confirm with trial site)
• People who received cellular therapy (such as CAR-T cell therapy) within the past 8 weeks
• People with significant fluid build-up around the heart or lungs, or fluid accumulation in the abdomen requiring drainage
• People with a heart condition called long QT syndrome, or whose heart electrical activity measurement (QTc interval) is above a certain level on a heart tracing (ECG) at the time of screening
• People with a known allergy or sensitivity to CD19-targeting antibodies or to any ingredient in the study medications
• People with active hepatitis B infection based on blood test results; people with certain hepatitis B markers may still be considered but would need to take preventive medication and have regular blood tests (confirm with trial site); people with hepatitis C may be considered in some circumstances if they are not currently being treated for it and liver function is otherwise acceptable (confirm with trial site)
• People with an active infection (bacterial, viral, fungal, or other) that requires treatment at the time of screening
• People with advanced chronic liver disease classified as Child-Pugh class C
• People who are pregnant, breastfeeding, or planning to become pregnant during the study
• People who have been diagnosed with another cancer within the past three years, or who have any remaining signs of a previous cancer — though some exceptions apply (such as certain skin cancers, early-stage prostate cancer, or certain in situ cancers), and the lead researcher may grant approval in some cases (confirm with trial site)
• People who are unable to tolerate steroid medications (corticosteroids)

Important: Always verify eligibility with the trial site directly before applying.